Study of MT1988 for people at high risk for psychosis
Part of Mental health clinical trials.
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 17 and 30 years old.
- You have been identified as being at clinical high risk for psychosis.
- If female and able to have children, you are not pregnant or nursing and agree to use birth control.
- You have no other major medical condition or history of schizophrenia or psychosis.
- You are willing to stop nicotine for 2 hours before cognitive tests and avoid marijuana on test days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called cannabidiol (a non-intoxicating compound from cannabis) can help reduce symptoms and prevent progression in young people at clinical high risk for psychosis. Participants will receive either the study drug or a placebo (a pill with no active ingredient) and will be followed to see how they respond.
This study uses brain imaging to look at dopamine activity in people at high risk for psychosis. The results may help improve future treatments.
This study tests whether a mindfulness program can help prevent psychosis in young people who are at ultra high risk. The goal is to see if learning mindfulness skills can protect your mental health and keep symptoms from getting worse.
This trial tests a new medicine called MT-201 to see if it is safe and how the body handles it. It is for healthy volunteers aged 19 to 55 who are willing to follow study rules.
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
This trial is testing a new medicine, NTX-253, to see how safe it is and how the body processes it. It is for healthy adults and adults with schizophrenia whose symptoms are stable on their current treatment.
Hear when a new Clinical High Risk for Psychosis (CHR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.